J.P. Morgan lowers Astellas Pharma target price to ¥2,300 and maintains Neutral

Overview

This is a model update report by J.P. Morgan on Astellas Pharma (4503.T). The report adjusts earnings forecasts based on 4QFY2025 results and the FY2026-30 medium-term plan, with the key changes being the incorporation of higher R&D investment and the medium-term margin trajectory, while lowering the target price to ¥2,300 and maintaining a Neutral rating.

Core views

The core view is that FY2026 earnings are supported by improved sales of Myrbetriq and key strategic products, yen depreciation, and other factors, leading to relatively constructive earnings forecasts; however, after FY2027, Xtandi patent expiry will usher in a profit downturn period, and together with approximately ¥2 trillion of R&D spending over five years, the achievability of the company’s 30% core operating profit margin target remains unclear. The stock lacks obvious near-term catalysts aside from quarterly earnings, and the medium-term key questions are whether strategic product ramp-up, SMT cost optimization, dividend support, and pipeline assets such as setidegrasib/ASP3082 and ASP2138 can drive an earlier profit trough.

Analysis framework

The report updates the earnings model using bottom-up product sales and expense assumptions, and derives the end-December 2026 target price using a 2027-36 DCF valuation model. Earnings forecasts also take into account the company’s medium-term plan, sales of the strategic five products, performance of Xtandi and Myrbetriq, the pace of R&D expenses, SMT cost optimization targets, FX assumptions, and the pipeline approval timetable.

Methodology notes

• Valuation methodsDCF

  Calculate the target price by discounting forecast cash flows from 2027 to 2036

  The target price of ¥2,300 is derived from a DCF model, assuming a terminal growth rate of 0% and a WACC of 8.7%, higher than the previous 7.8%. This target price corresponds to approximately 5.4x EV/EBITDA on FY2027 EBITDA and approximately 5.3x on FY2031 EBITDA.

• Earnings forecastMedium-term plan budget adjustment

  Incorporate R&D expense and margin targets from the FY2026-30 medium-term plan into the model

  The report incorporates approximately ¥2 trillion of R&D expenses over the next five years into forecasts, while also incorporating the company’s SMT target levels; J.P. Morgan’s forecasts for FY2027-31 core operating profit margins are below the company’s 30% target, reflecting uncertainty around high R&D investment and the pace of product growth.

• Scenarios and risksUpside and downside scenarios for target price/rating

  Assess rating risk around profit growth, shareholder returns, and pipeline data

  Upside scenarios include better-than-expected profit growth, shareholder returns, and development product data; downside scenarios include lower-than-expected profit levels or shareholder returns.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Astellas Pharma (4503.T)

  Covered company in the report; a Japanese pharmaceutical equity.

  Strengths

  FY2026 core operating profit forecast is above company guidance and consensus; strong sales of Myrbetriq and the strategic five products; the company is pursuing SMT cost optimization and plans to maintain DPS growth of at least ¥2 per year; pipeline assets such as setidegrasib/ASP3082 and ASP2138 offer potential catalysts.

  Weaknesses

  After FY2027, the company enters a post-Xtandi-patent-expiry profit downturn period; approximately ¥2 trillion of R&D investment over five years depresses medium-term margins; J.P. Morgan forecasts core operating profit margins below the company’s 30% target; near-term catalysts are limited outside quarterly earnings.

  Comparison

  The target price of ¥2,300 offers only approximately 7.2% upside versus the current price of ¥2,145; FY2026 earnings forecasts are relatively optimistic, but FY2028-30 core operating profit forecasts have been lowered, and long-term margins remain below management targets.

  Risks

  If profit growth, shareholder returns, or development product data exceed expectations, the rating and target price could move higher; if profit levels or shareholder returns disappoint, or pipeline progress falls short of expectations, the target price and rating face downside risk.

Key data

• Current share price¥2,145Price as of June 26, 2026.
• Target price¥2,300Target price for end-December 2026; previous value was ¥2,500.
• Analyst ratingNeutralJ.P. Morgan maintains a Neutral rating.
• Implied upsideapproximately 7.2%Calculated based on the target price of ¥2,300 and the current price of ¥2,145.
• R&D investment assumption for the next five yearsapproximately ¥2 trillionHigher than the previous assumption and an important reason for lowering medium- to long-term profit forecasts.
• FY2026 core operating profit forecast¥655.7 billion, up 18.0% year-on-yearAbove company guidance of ¥620.0 billion and Bloomberg consensus of ¥621.3 billion.
• FY2026 IFRS operating profit forecast¥448.1 billion, up 17.1% year-on-yearCompany guidance is ¥395.0 billion, while Bloomberg consensus is ¥454.4 billion.
• FY2030 strategic five products sales forecast¥947.0 billionClose to the company target; the company target is about double FY2025's approximately ¥480 billion.
• WACC8.7%Previously 7.8%.
• Terminal growth rate0%Used for DCF valuation.
• FY2027 EBITDA estimate¥683.2 billionThe target price implies approximately 5.4x EV/EBITDA.
• FY2031 EBITDA estimate¥511.8 billionThe target price implies approximately 5.3x EV/EBITDA.

Impact & implications

For investors, the report conveys a cautious neutral signal: near-term FY2026 results may exceed company guidance, but the medium-term profit trajectory is constrained by Xtandi patent expiry, high R&D investment, and uncertainty over achieving margin targets. The company’s plan to increase DPS by at least ¥2 annually may support the share price, but valuation rerating room is limited unless strategic product growth, SMT cost reductions, and pipeline data can quickly demonstrate that profits are bottoming.

Risks

• Xtandi patent expiry may lead to profit decline after FY2027.
• High R&D investment creates uncertainty around the achievability of the 30% core operating profit margin target.
• Pipeline data, trial starts, or approval timing for setidegrasib/ASP3082, ASP2138, and other assets may fall short of expectations.
• Sales growth of the strategic five products, non-strategic product sales, SMT cost reduction effects, and the annual pace of R&D expenses may all diverge from forecasts.
• If shareholder returns are below expectations, share price support may weaken.
• Differences in FX assumptions may affect revenue and profit forecasts.

What to watch

• Whether 1QFY2026 results reach J.P. Morgan’s forecast of core operating profit of ¥171.4 billion.
• Whether full-year FY2026 core operating profit can exceed company guidance of ¥620.0 billion.
• Additional data planned for disclosure within the current fiscal year for setidegrasib/ASP3082 and ASP2138.
• Whether more than five Phase 3 or pivotal trials can be initiated before FY2027, and progress toward more than ten trials during the medium-term plan period.
• Whether sales of the strategic five products progress toward the FY2030 forecast of ¥947.0 billion.
• Whether SMT cost optimization can achieve the company’s ¥200 billion target and support margins.
• Whether the company’s shareholder return plan of increasing DPS by at least ¥2 annually continues to be delivered.